Phase 1b Trial of Beloranib, a Novel Methionine Aminopeptidase 2 (MetAP-2) Inhibitor for Treatment of Extreme Obesity: Randomized, Double-Blind, Placebo-Controlled, Escalating Doses in Female Volunteers

Trial Profile

Phase 1b Trial of Beloranib, a Novel Methionine Aminopeptidase 2 (MetAP-2) Inhibitor for Treatment of Extreme Obesity: Randomized, Double-Blind, Placebo-Controlled, Escalating Doses in Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2012

At a glance

  • Drugs Beloranib (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 24 Sep 2012 Results presented at the 2012 Annual Meeting of the North American Association for the Study of Obesity.
    • 22 Sep 2012 Results were presented at the 30th Annual Scientific Meeting of the Obesity Society according to a Zafgen media release. Results were also reported in the media release.
    • 10 Jun 2012 Results were reported at the 72nd Annual Scientific Sessions of the American Diabetes Association, according to a Zafgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top